Kadcyla is ananti-cancer medication which will prevents the growth and spread of cancer cells in the body Emtansine is known as MCC-DM1 complex.
Kadcyla is well defined as recombinant monoclonal antibody product by mammalian cells and DM1 and MCC produced by chemical synthesis.
Kadcyla is normally used after other chemo drugs have been tried and failed to give success.

Ado-trastuzumab emtansine


160mg per vial


Kadcyla is a single component which indicated for the treatment of HER-2positive metastatic breast cancer, the treatment given for who previously received trastuzumab and a taxane in combination or alone treatment. Patients have either two conditions
1. Previously got treatment for metastatic disease
2. Relapsed during or within six months of completing adjuvant therapy

Mechanism of action

Ado-trastuzumab emtansine is a type of HER2-antibody drug conjugate which consolidated the HER2 aimed actions of trastuzumab with the microtubule inhibitor DM1 (a maytansine derivative).
The conjugate, which is joined through a stable thioether linker, allows for selective delivery into HER2 overexpressing cells, resulting in cell cycle arrest and apoptosis


The time to peak plasma concentration is near the end of the infusion

DM1 has serum protein concentration is 93%

Kadcyla undergoes hepatic metabolism through CYP3A4/5

Half-life is approximately 4 days


Ingredients Ado-trastuzumab Emtansine
Strength 100mg
Pack 160mg per vial

Kadcyla recommended dose for adult dose is 3.6mg/kg administer every 3 weeks (21-day cycle).
Treatment received until disease progression or unacceptable toxicity
More than 3.6mg/kg dose should not administer to the patients
Do not substitute other medicine for kadcyla or with trastuzumab
Administer kadcyla injection over 90minutes in first infusion.
Followed by subsequent infusions over 30 minutes.

Kadcyla help to prevent breast cancer in which it may cause some serious and common side effects. Inform your doctor If any of these signs or symptoms occurs or do not cure soon.
Common side effects :
• Stomach upset
• Constipation
• Mouth ulcer, throat ulcer
• Dry mouth
• Joint or muscle pain
• Headache
• Dry, red or teary eyes
• Vision blurred
• Insomnia
Some serious side effects :
• Where the medication was injected in the place Pain, itching, redness, swelling, blisters, or sores.
• Nosebleeds and other unusual bleeding or bruising
• Bloody or black, tarry stools
• In the hands or feet pain, burning or tingling
• Hives
• Rash
• Breathing difficulty.


Severe hepatotoxicity, which involves in liver failure and death has been identified. Transaminases and bilirubin at baseline and prior to each dose should be monitor, If dose increases then require dose reduction or discontinuation.
Left ventricular dysfunction:
During treatment, evaluate the function of left ventricular function before or at least every 3 months. If any significant function of left ventricular decreases, then withhold the kadcyla treatment
Embryo-fetal toxicity:
When kadcyla administer to pregnant women it will cause harm to the patients. Based on its mechanism of action, the antibody and cytotoxic components of kadcyla will cause embryo-fetal toxicity
Pulmonary toxicity:
Permanently discontinue kadcyla treatment in patients having ILD or pneumonitis


  • Kadcyla has no formal drug- drug interaction but conducting in vitro studies some interaction as follows

  • Interaction with CYP3A4 inhibitors may increase the CYP3A4 substrates serum concentration.

  • While interaction with anthracyclines, the cardiotoxic effects may enhance for anthracyclines.

  • Interaction with tacrolimus the adverse/toxic effects of immunosuppressants may increase.

  • Kadcyla concomitant use with trastuzumab then it may enhance the neutropenic effect of immunosuppressants

Missed Dose

If any dose missed, then take it when remember before the next dose.
If time reaches for next dose, then skip missed dose.
Follow the regular schedule. do not have double dose at same time
Please consult the doctor for further details

The drug kadcyla may cause harm to fetal when administer to the pregnant women. Oligohydramnios and oligohydramnios sequence may signify as abnormalities in skeletal and pulmonary hypoplasia and finally neonatal death were noticed.
During breast feeding usage of kadcyla should be avoided, Excretion into human milk is unknown. There is no information regarding using during breast feeding because of large protein molecule

Store at 2°C- 8°C
Protect from light

Quick Contact

Prescription upload

PRESCRIPTION , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines. will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website. requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from

At , a Caregiver can order prescription medicines on your behalf.